

MAIL STOP AMENDMENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: K. Foster et al. Attorney Docket No.: MASQ127218
 Application No.: 10/571,515 ✓ Art Unit: 1651
 Filed: March 10, 2006 Confirmation No.: 8062
 Title: DESIGN OF RE-TARGETED TOXIN CONJUGATES

INFORMATION DISCLOSURE STATEMENT

Seattle, Washington 98101

February 20, 2007

TO THE COMMISSIONER FOR PATENTS:

Applicants are aware of the information listed in the attached form that may be material to the prosecution of the above-identified patent application.

1. X Copies of the listed foreign publications and non-patent literature are enclosed for the Examiner's use.
2. X Pursuant to 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits.

Respectfully submitted,

CHRISTENSEN O'CONNOR
 JOHNSON KINDNESS^{PLLC}



George E. Renzoni, Ph.D.
 Registration No. 37,919
 Direct Dial No. 206.695.1755

I hereby certify that this correspondence is being deposited with the U.S. Postal Service in a sealed envelope as first-class mail with postage thereon fully prepaid and addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the below date.

Date: February 20, 2007

GER:md

LAW OFFICES OF
 CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
 1420 Fifth Avenue
 Suite 2800
 Seattle, Washington 98101
 206.682.8100



INFORMATION CITED BY APPLICANTS THAT MAY BE MATERIAL TO THE
PROSECUTION OF THE SUBJECT APPLICATION

Applicants: K. Foster et al. Attorney Docket No.: MASQ127218
 Application No.: 10/571,515 Art Unit: 1651
 Filed: March 10, 2006 Confirmation No.: 8062
 Title: DESIGN OF RE-TARGETED TOXIN CONJUGATES

U.S. PATENT DOCUMENTS

*Examiner Initials	Cite No.	Document No.	Kind Code	Date (mm/dd/yyyy)	Name
_____	U1	6,461,617	B1	10/8/2002	Shone et al.
_____	U2	2003/0059912	A1	03/27/2003	Bigalke et al.

FOREIGN PATENT DOCUMENTS

*Examiner Initial	Cite No.	Document No.	Kind Code	Publication Date (mm/dd/yyyy)	Country	English Abstract Provided	Translation Provided
_____	F1	EP 0 467 536	A2	01/22/1992	EP		
_____	F2	WO 94/21300	A2	09/29/1994	WO		
_____	F3	WO 97/10335	A1	03/02/1997	WO	X	
_____	F4	WO 98/07864	A1	02/26/1998	WO		
_____	F5	WO 99/58571	A2	11/18/1999	WO	X	
_____	F6	WO 00/10598	A2	03/02/2000	WO		
_____	F7	WO 00/64932	A1	11/2/2000	WO	X	

/Sheridan Swopa/

08/11/2008

LAW OFFICES OF
 CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
 1420 Fifth Avenue
 Suite 2800
 Seattle, Washington 98101
 206.682.8100

OTHER INFORMATION

(Including Author, Title, Date, Pertinent Pages, Etc.)

*Examiner Initial	Cite No.
_____	O1 Abdulla P., and G. Forstner, "GTP and CA^{2+} -Dependent Mucin Secretion in Permeabilized LS180 Human Colonic Cancer Cells: Modulation by Anion Substitution," <i>FASEB Journal</i> 11(3):A516, 1997.
_____	O2 Cain, C.C., et al., "Members of the VAMP Family of Synaptic Vesicle Proteins are Components of Glucose Transporter-Containing Vesicles from Rat Adipocytes," <i>The Journal of Biological Chemistry</i> 267(17):11681-11684, June 15, 1992.
_____	O3 Davis, Roger J., et al., "Insulin-Like Growth Factor I and Epidermal Growth Factor Regulate the Expression of Transferrin Receptors at the Cell Surface by Distinct Mechanisms," <i>The Journal of Biological Chemistry</i> 262(27):13126-13134, September 25, 1987.
_____	O4 Debinski, W., et al., "A Novel Chimeric Protein Composed by Interleukin 13 and <i>Pseudomonas</i> Exotoxin Is Highly Cytotoxic to Human Carcinoma Cells Expressing Receptors for Interleukin 13 and Interleukin 4," <i>The Journal of Biological Chemistry</i> 270(28):16775-16780, July 14, 1995.
_____	O5 Enss, M.-L., et al., "Proinflammatory Cytokines Differentially Affect Mucin Expression in LS180 Cells," <i>Gastroenterology</i> 114(4, part 2):A973, April, 15, 1998.
_____	O6 Enss, M.-L., et al., "Proinflammatory Cytokines Trigger <i>MUC</i> Gene Expression and Mucin Release in the Intestinal Cancer Cell Line LS180," <i>Inflammation Research</i> 49(4):162-169, April 2000.
_____	O7 Jayawickreme, S.P., et al., "Regulation of 15-Lipoxygenase Expression and Mucus Secretion by IL-4 in Human Bronchial Epithelial Cells," <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> 276(4 20-4):L596-L603, 1999.
_____	O8 Li, D., et al., "Hyperosmolarity Reduces GLUT4 Endocytosis and Increases Its Exocytosis from a VAMP2-Independent Pool in L6 Muscle Cells," <i>The Journal of Biological Chemistry</i> 276(25):22883-22891, June 22, 2001.
_____	O9 Olson, A.L., et al., "Insulin-Mediated Glut4 Translocation Is Dependent on the Microtubule Network," <i>The Journal of Biological Chemistry</i> 276(14):10706-10714, April 6, 2001.

/Sheridan Swope/

08/11/2008

LAW OFFICES OF
 CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{LLC}
 1420 Fifth Avenue
 Suite 2800
 Seattle, Washington 98101
 206.682.8100

MASQ272181-1-0000

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.S./

*Examiner Cite
Initial No.

-
- O10 Skeberdis, V.A., et al., "Insulin Promotes Rapid Delivery of N-methyl-D-Aspartate Receptors to the Cell Surface by Exocytosis," *Proceedings of the National Academy of Sciences of the United States of America* 98(6):3561-3566, March 13, 2001.
-
- O11 Yang, C.Z., and M. Mueckler, "ADP-Ribosylation Factor (AFR6) Defines Two Insulin-Regulated Secretory Pathways in Adipocytes," *The Journal of Biological Chemistry* 274(36):25297-25300, September 3, 1999.

Examiner

Date Considered

/Sheridan Swope/

08/11/2008

*Examiner: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

GER:md

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100